Effect of Stem-Kine Food Supplement on Circulating Stem Cells

ISRCTN ISRCTN25688299
DOI https://doi.org/10.1186/ISRCTN25688299
Secondary identifying numbers 2009-02
Submission date
08/02/2010
Registration date
25/02/2010
Last edited
16/08/2011
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Nina Mikirova
Scientific

3100 North Hillside Avenue
Wichita
67219
United States of America

Study information

Study designObservational
Primary study designObservational
Secondary study designCohort study
Study setting(s)Other
Study typeOther
Participant information sheet Not available in web format, please use contact below to request a patient information sheet.
Scientific titleEffect of Stem-Kine Food Supplement on Circulating Stem Cells: an observational trial
Study acronymESFSCSC
Study objectivesThe food supplement Stem-Kine may cause a modulation of circulating stem cell numbers in healthy volunteers
Ethics approval(s)Institutional Review Board of The Center for Improvement of Human Health International, Wichita, Kansas, USA approved on the 29th of July 2009 (ref: 2009-02)
Health condition(s) or problem(s) studiedHealthy Volunteers
InterventionIngestion of the commercially-available food supplement Stem-Kine:
Two 8 ml blood draws in heparinized Vacutainer tubes are collected by venipuncture before administration of Stem-Kine supplementation (day 0) and at days 1, 2, 7, and 14. Study participants are required to ingest two capsules of Stem-Kine (700mg/capsule) in the morning and two in the evening for 14 days.
Comparison is made pre- and post- treatment all recruited subjects.
Intervention typeOther
Primary outcome measureAlteration in circulating hematopoietic and endothelial progenitor cells.
Blood samples taken pre-supplementation (day 0), and at days 1, 2, 7, and 14 are analyzed by flow cytometry and colony forming assays
Secondary outcome measuresChanges in overall health/mood, based on self reporting
Overall study start date01/08/2009
Completion date01/12/2009

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants18
Key inclusion criteria1. Healthy adults, ages 20-72
2. Signed informed consent
Key exclusion criteria1. Systemic immune-compromised state
2. Ongoing infection or disease conditions
3. Significant abnormalities in biochemistry or complete blood count panels
Date of first enrolment01/08/2009
Date of final enrolment01/12/2009

Locations

Countries of recruitment

  • United States of America

Study participating centre

3100 North Hillside Avenue
Wichita
67219
United States of America

Sponsor information

Medistem Inc (USA)
Industry

9255 Towne Centre Drive, Suite 450
San Diego
92122
United States of America

ROR logo "ROR" https://ror.org/03andxb27

Funders

Funder type

Charity

Allan P Markin (Canada) - individual funder

No information available

The Aidan Foundation (USA)

No information available

The Center For The Improvement Of Human Functioning International (USA)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan